Vanguard Group Inc Legend Biotech Corp Transaction History

Vanguard Group Inc

$5.97 Trillion
Q2 2025

A detailed history of Vanguard Group Inc transactions in Legend Biotech Corp stock. As of the latest transaction made, Vanguard Group Inc holds 122,032 shares of LEGN stock, worth $3.95 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

122,032

Previous 135,506 9.94%

Holding current value

$3.95 Million

Previous $4.6 Million 5.81%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2025 Aug 11, 2025	SELL	$27.69 - $37.91 $373,095 - $510,799	-13,474 Reduced 9.94%	122,032 $4.33 Million
Q1 2025 May 09, 2025	BUY	$31.43 - $39.7 $220,418 - $278,416	7,013 Added 5.46%	135,506 $4.6 Million
Q4 2024 Feb 11, 2025	BUY	$32.49 - $50.28 $154,457 - $239,031	4,754 Added 3.84%	128,493 $4.18 Million
Q2 2024 Aug 13, 2024	SELL	$39.5 - $57.22 $221,990 - $321,576	-5,620 Reduced 4.34%	123,739 $5.48 Million
Q1 2024 May 10, 2024	BUY	$55.06 - $69.99 $40,634 - $51,652	738 Added 0.57%	129,359 $7.26 Million
Q4 2023 Feb 14, 2024	BUY	$57.25 - $69.74 $791,252 - $963,876	13,821 Added 12.04%	128,621 $7.74 Million
Q2 2023 Aug 14, 2023	SELL	$46.28 - $75.01 $38,551 - $62,483	-833 Reduced 0.72%	114,800 $7.92 Million
Q1 2023 May 15, 2023	BUY	$43.42 - $57.37 $1.2 Million - $1.59 Million	27,649 Added 31.43%	115,633 $5.58 Million
Q3 2022 Nov 14, 2022	BUY	$38.15 - $57.1 $170,072 - $254,551	4,458 Added 5.34%	87,984 $3.59 Million
Q2 2022 Aug 12, 2022	BUY	$33.54 - $55.0 $191,513 - $314,050	5,710 Added 7.34%	83,526 $4.59 Million
Q4 2021 Feb 14, 2022	BUY	$41.14 - $56.98 $3.2 Million - $4.43 Million	77,816 New	77,816 $3.63 Million

Others Institutions Holding LEGN

# of Institutions

238

Shares Held

59.7M

Call Options Held

591K

Put Options Held

381K

View Full List

About Legend Biotech Corp

Ticker LEGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 167,403,008
Market Cap $5.42B
Description
Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...

More about LEGN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.

Account

Vanguard Group Inc Legend Biotech Corp Transaction History